Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Upper Michigan Brain Tumor Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glioma | patients who are diagnosed with and are being treated for glioma |
| |
| meningioma | patients who are diagnosed with and are being treated for meningioma |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood test | Procedure | an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test |
| Measure | Description | Time Frame |
|---|---|---|
| Determine if VEGF levels correlate with tumor progression or recurrence | every one to three months |
| Measure | Description | Time Frame |
|---|---|---|
| Determine if the VEGF level is an indicator of the response to treatment. | Every one to three months | |
| Determine if the VEGF level correlates with tumor histology and behavior. | Every one to three months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis of meningioma or glioma
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard A Rovin, MD, FACS | Upper Michigan Brain Tumor Center | Principal Investigator |
| Robert J Winn, PhD | Northern Michigan University | Principal Investigator |
| Suresh Nukala, MD | Marquette General Health Systems | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Marquette General Hospital | Marquette | Michigan | 49855 | United States |
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| D008579 | Meningioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D006403 | Hematologic Tests |
| ID | Term |
|---|---|
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
serum
|
| Determine if there is a relationship between VEGF level and outcome. | Every one to three months |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D009383 | Neoplasms, Vascular Tissue |
| D008577 | Meningeal Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009422 | Nervous System Diseases |